• EdU Imaging Kits (Cy5): Precision Cell Proliferation Analysi

  2026-05-01

  EdU Imaging Kits (Cy5) enable high-sensitivity, morphology-preserving detection of S-phase DNA synthesis in proliferating cells. This 5-ethynyl-2'-deoxyuridine imaging kit uses click chemistry, offering superior specificity over BrdU assays and robust compatibility with fluorescence microscopy and flow cytometry.

• DCPS Identified as a Key m7G Biomarker in Diabetic Foot Ulce

  2026-05-01

  This study identifies the decapping scavenger enzyme (DCPS), an m7G-related gene, as a promising biomarker and regulator of epithelial cell function in diabetic foot ulcers (DFUs). By integrating bioinformatic analyses and functional experiments, the authors demonstrate that DCPS modulates cell cycle progression, proliferation, and migration in keratinocytes, offering new insight into chronic wound pathology and potential therapeutic targets.

• Concanamycin A: Unlocking Lysosomal Control in Cancer Resear

  2026-04-30

  This thought-leadership article explores the mechanistic and strategic value of Concanamycin A, a gold-standard V-type H+-ATPase inhibitor, for translational researchers in oncology and metabolic disease. We dissect its role in modulating lysosomal acidification, driving apoptosis in tumor cells, and informing therapeutic resistance studies, with unique insights drawn from recent advances in nutrient sensing and metabolic adaptation. The discussion integrates evidence from leading literature—including the pivotal role of TCF25 in lysosomal-mediated cell death—while providing practical guidance for experimental design and translational strategy. Key protocol recommendations, competitive positioning, and outlook toward next-generation applications are provided, offering a fresh, SEO-driven synthesis beyond standard product or review articles.

• Cisplatin in Cancer Research: Protocols and Resistance Insig

  2026-04-30

  Harness Cisplatin (CDDP) for advanced cancer research with workflow-optimized protocols and troubleshooting guidance. This article bridges bench science and translational oncology, spotlighting chemoresistance mechanisms and experimental best practices.

• Nirmatrelvir (PF-07321332): Optimizing SARS-CoV-2 Research W

  2026-04-29

  Nirmatrelvir (PF-07321332) stands out as a potent tool for dissecting coronavirus replication and advancing antiviral therapeutics research. This article details experimental strategies, workflow optimization, and troubleshooting tips tailored for maximizing the compound's value in SARS-CoV-2 inhibition studies.

• Mifepristone (RU486): Applied Protocols for Cancer & Fertili

  2026-04-29

  Mifepristone (RU486) empowers precision research in oncology and reproductive biology by targeting progesterone receptor pathways. This article delivers actionable workflows, troubleshooting strategies, and evidence-driven insights—maximizing reproducibility with high-purity Mifepristone from APExBIO.

• OTC-Ornithine Axis in Realgar-Induced CNS Toxicity: Mechanis

  2026-04-28

  This study elucidates how realgar-derived arsenic disrupts the liver–brain metabolic axis, showing that hepatic OTC inhibition leads to ornithine accumulation and contributes to CNS toxicity via ZBTB7A-mediated repression of astrocyte glycolysis. The findings clarify a mechanistic link between urea cycle dysfunction and neurotoxicity, offering new molecular targets for mitigating adverse effects of realgar exposure.

• Dual Luciferase Reporter Gene System: Precision for Fine-Tun

  2026-04-28

  Discover how the Dual Luciferase Reporter Gene System empowers nuanced gene expression regulation and transcriptional studies, with a special focus on plant defense. This article highlights its scientific underpinnings, protocol essentials, and practical applications beyond standard workflows.

• Phillygenin Modulates Inflammation and Apoptosis in Diabetic

  2026-04-27

  This study demonstrates that phillygenin, a bioactive compound from Forsythia suspensa, significantly alleviates inflammation and apoptosis in diabetic nephropathy by modulating the TLR4/MyD88/NF-κB and PI3K/AKT/GSK3β pathways. The findings provide mechanistic insight and highlight phillygenin's potential as a novel therapeutic agent for diabetic kidney injury.

• Tunicamycin (SKU B7417): Reliable N-Glycosylation Inhibitor

  2026-04-27

  This article delivers a scenario-driven, evidence-based guide to using Tunicamycin (SKU B7417) in studies of ER stress, glycosylation, and inflammation. Addressing challenges in assay reproducibility, specificity, and protocol optimization, it demonstrates how APExBIO’s Tunicamycin enables robust, publication-quality results for cell viability and inflammation suppression workflows.

• Tunicamycin: Gold-Standard N-Glycosylation Inhibitor for ER

  2026-04-26

  Tunicamycin is a potent, well-characterized N-glycosylation inhibitor. It induces endoplasmic reticulum (ER) stress, facilitating precise study of the unfolded protein response and inflammation pathways. Its applications in macrophage assays and hepatic models are evidence-backed and reproducible.

• n-Alkyl Modified Copper Ionophores Drive Efficient Cuproptos

  2026-04-25

  This study rationally designs a series of n-alkyl modified copper ionophores, revealing how simple chain length adjustments optimize the induction of cuproptosis in cancer cells. The work identifies C6 as a lead compound, demonstrating selective anti-proliferative and immunomodulatory activity with minimal systemic toxicity, offering new strategies for metal-based cancer therapeutics.

• DiD (DiDC 18 (5)) Plasma Membrane Red Fluorescent Probe: Rel

  2026-04-24

  This article presents an evidence-driven, scenario-based guide to optimizing cell membrane staining, migration tracking, and assay reproducibility with DiD (DiDC 18 (5)) Plasma Membrane Red Fluorescent Probe (SKU B8805). Drawing on published research and validated workflows, it demonstrates how this probe resolves key challenges in high-autofluorescence samples, complex immunofluorescence, and vendor selection. Discover best practices and protocol parameters for dependable results.

• Liproxstatin-1: Precision Ferroptosis Inhibition for Applied

  2026-04-24

  Liproxstatin-1 stands out as a potent ferroptosis inhibitor, enabling precise modulation of iron-dependent cell death across disease models. This article delivers actionable, evidence-backed protocols and troubleshooting strategies, drawing on recent mechanistic advances and comparative benchmarks to optimize your ferroptosis research with APExBIO’s Liproxstatin-1.

• Mifepristone (RU486): Expanding the Translational Frontier

  2026-04-23

  Explore how Mifepristone (RU486), a potent progesterone receptor antagonist, is redefining translational research across oncology and reproductive biology. This thought-leadership article integrates mechanistic insights, protocol guidance, and competitive context, while providing actionable strategies for researchers leveraging APExBIO’s high-purity reagent.

11289 records 1/753 page Next 12345 下5页 Last page